Remove 2017 Remove Drug Development Remove Therapies
article thumbnail

The evolution of cell therapy to address unmet medical needs

Drug Target Review

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

Transposon technologies are gaining traction due to their accuracy in integrating the gene of interest into the host genome, making them an important tool for accelerating large molecule drug development. 2017 Nov;33(6):1468-1475. Epub 2017 Sep 7. Cell Gene Therapy Insights 2017; 3(2), 131-158, 10.18609/cgti.2017.014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

article thumbnail

A research team searches for every gene that helps tumors evade immunotherapy

Broad Institute

But immunotherapy was not yet widely used and had not been applied clinically to Merkel cell carcinoma, so she received traditional chemotherapy and radiation therapy, suffering life-threatening complications along the way. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137
article thumbnail

Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial

The Pharma Data

. Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma. The therapy is a one-time treatment created individually for each patient using their own T cells.

article thumbnail

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Advarra

Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating gene therapies.

article thumbnail

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

The Pharma Data

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc.